No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer

Antoinette Hollestelle; Frederieke H van der Baan; Andrew Berchuck; Sharon E Johnatty; Katja K Aben; Bjarni A Agnarsson; Kristiina Aittomäki; Elisa Alducci; Irene L Andrulis; Hoda Anton-Culver; Natalia N Antonenkova; Antonis C Antoniou; Carmel Apicella; Volker Arndt; Norbert Arnold; Banu K Arun; Brita Arver; Alan Ashworth; Laura Baglietto; Rosemary Balleine; Elisa V Bandera; Daniel Barrowdale; Yukie T Bean; Lars Beckmann; Matthias W Beckmann; Javier Benitez; Andreas Berger; Raanan Berger; Benoit Beuselinck; Maria Bisogna; Line Bjorge; Carl Blomqvist; Natalia V Bogdanova; Anders Bojesen; Stig E Bojesen; Manjeet K Bolla; Bernardo Bonanni; Judith S Brand; Hiltrud Brauch; Hermann Brenner; Louise Brinton; Angela Brooks-Wilson; Fiona Bruinsma; Joan Brunet; Thomas Brüning; Agnieszka Budzilowska; Clareann H Bunker; Barbara Burwinkel; Ralf Butzow; Inge Sokilde Pedersen; Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2

doi:10.1016/j.ygyno.2015.04.034

No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer

Antoinette Hollestelle, Frederieke H van der Baan, Andrew Berchuck, Sharon E Johnatty, Katja K Aben, Bjarni A Agnarsson, Kristiina Aittomäki, Elisa Alducci, Irene L Andrulis, Hoda Anton-Culver, Natalia N Antonenkova, Antonis C Antoniou, Carmel Apicella, Volker Arndt, Norbert Arnold, Banu K Arun, Brita Arver, Alan Ashworth, Laura Baglietto, Rosemary BalleineElisa V Bandera, Daniel Barrowdale, Yukie T Bean, Lars Beckmann, Matthias W Beckmann, Javier Benitez, Andreas Berger, Raanan Berger, Benoit Beuselinck, Maria Bisogna, Line Bjorge, Carl Blomqvist, Natalia V Bogdanova, Anders Bojesen, Stig E Bojesen, Manjeet K Bolla, Bernardo Bonanni, Judith S Brand, Hiltrud Brauch, Hermann Brenner, Louise Brinton, Angela Brooks-Wilson, Fiona Bruinsma, Joan Brunet, Thomas Brüning, Agnieszka Budzilowska, Clareann H Bunker, Barbara Burwinkel, Ralf Butzow, Inge Sokilde Pedersen, Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2

Research output: Contribution to journal › Review article › peer-review

11 Citations (Scopus)

Abstract

OBJECTIVE: Clinical genetic testing is commercially available for rs61764370, an inherited variant residing in a KRAS 3' UTR microRNA binding site, based on suggested associations with increased ovarian and breast cancer risk as well as with survival time. However, prior studies, emphasizing particular subgroups, were relatively small. Therefore, we comprehensively evaluated ovarian and breast cancer risks as well as clinical outcome associated with rs61764370.

METHODS: Centralized genotyping and analysis were performed for 140,012 women enrolled in the Ovarian Cancer Association Consortium (15,357 ovarian cancer patients; 30,816 controls), the Breast Cancer Association Consortium (33,530 breast cancer patients; 37,640 controls), and the Consortium of Modifiers of BRCA1 and BRCA2 (14,765 BRCA1 and 7904 BRCA2 mutation carriers).

RESULTS: We found no association with risk of ovarian cancer (OR=0.99, 95% CI 0.94-1.04, p=0.74) or breast cancer (OR=0.98, 95% CI 0.94-1.01, p=0.19) and results were consistent among mutation carriers (BRCA1, ovarian cancer HR=1.09, 95% CI 0.97-1.23, p=0.14, breast cancer HR=1.04, 95% CI 0.97-1.12, p=0.27; BRCA2, ovarian cancer HR=0.89, 95% CI 0.71-1.13, p=0.34, breast cancer HR=1.06, 95% CI 0.94-1.19, p=0.35). Null results were also obtained for associations with overall survival following ovarian cancer (HR=0.94, 95% CI 0.83-1.07, p=0.38), breast cancer (HR=0.96, 95% CI 0.87-1.06, p=0.38), and all other previously-reported associations.

CONCLUSIONS: rs61764370 is not associated with risk of ovarian or breast cancer nor with clinical outcome for patients with these cancers. Therefore, genotyping this variant has no clinical utility related to the prediction or management of these cancers.

Original language	English
Journal	Gynecologic Oncology
Volume	141
Issue number	2
Pages (from-to)	386-401
Number of pages	16
ISSN	0090-8258
DOIs	https://doi.org/10.1016/j.ygyno.2015.04.034
Publication status	Published - 2016

Access to Document

10.1016/j.ygyno.2015.04.034

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

Hollestelle, A., van der Baan, F. H., Berchuck, A., Johnatty, S. E., Aben, K. K., Agnarsson, B. A., Aittomäki, K., Alducci, E., Andrulis, I. L., Anton-Culver, H., Antonenkova, N. N., Antoniou, A. C., Apicella, C., Arndt, V., Arnold, N., Arun, B. K., Arver, B., Ashworth, A., Baglietto, L., ... Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2 (2016). No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 141(2), 386-401. https://doi.org/10.1016/j.ygyno.2015.04.034

@article{739edcb9636e4e9e83c849744028aac1,

title = "No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer",

abstract = "OBJECTIVE: Clinical genetic testing is commercially available for rs61764370, an inherited variant residing in a KRAS 3' UTR microRNA binding site, based on suggested associations with increased ovarian and breast cancer risk as well as with survival time. However, prior studies, emphasizing particular subgroups, were relatively small. Therefore, we comprehensively evaluated ovarian and breast cancer risks as well as clinical outcome associated with rs61764370.METHODS: Centralized genotyping and analysis were performed for 140,012 women enrolled in the Ovarian Cancer Association Consortium (15,357 ovarian cancer patients; 30,816 controls), the Breast Cancer Association Consortium (33,530 breast cancer patients; 37,640 controls), and the Consortium of Modifiers of BRCA1 and BRCA2 (14,765 BRCA1 and 7904 BRCA2 mutation carriers).RESULTS: We found no association with risk of ovarian cancer (OR=0.99, 95% CI 0.94-1.04, p=0.74) or breast cancer (OR=0.98, 95% CI 0.94-1.01, p=0.19) and results were consistent among mutation carriers (BRCA1, ovarian cancer HR=1.09, 95% CI 0.97-1.23, p=0.14, breast cancer HR=1.04, 95% CI 0.97-1.12, p=0.27; BRCA2, ovarian cancer HR=0.89, 95% CI 0.71-1.13, p=0.34, breast cancer HR=1.06, 95% CI 0.94-1.19, p=0.35). Null results were also obtained for associations with overall survival following ovarian cancer (HR=0.94, 95% CI 0.83-1.07, p=0.38), breast cancer (HR=0.96, 95% CI 0.87-1.06, p=0.38), and all other previously-reported associations.CONCLUSIONS: rs61764370 is not associated with risk of ovarian or breast cancer nor with clinical outcome for patients with these cancers. Therefore, genotyping this variant has no clinical utility related to the prediction or management of these cancers.",

author = "Antoinette Hollestelle and {van der Baan}, {Frederieke H} and Andrew Berchuck and Johnatty, {Sharon E} and Aben, {Katja K} and Agnarsson, {Bjarni A} and Kristiina Aittom{\"a}ki and Elisa Alducci and Andrulis, {Irene L} and Hoda Anton-Culver and Antonenkova, {Natalia N} and Antoniou, {Antonis C} and Carmel Apicella and Volker Arndt and Norbert Arnold and Arun, {Banu K} and Brita Arver and Alan Ashworth and Laura Baglietto and Rosemary Balleine and Bandera, {Elisa V} and Daniel Barrowdale and Bean, {Yukie T} and Lars Beckmann and Beckmann, {Matthias W} and Javier Benitez and Andreas Berger and Raanan Berger and Benoit Beuselinck and Maria Bisogna and Line Bjorge and Carl Blomqvist and Bogdanova, {Natalia V} and Anders Bojesen and Bojesen, {Stig E} and Bolla, {Manjeet K} and Bernardo Bonanni and Brand, {Judith S} and Hiltrud Brauch and Hermann Brenner and Louise Brinton and Angela Brooks-Wilson and Fiona Bruinsma and Joan Brunet and Thomas Br{\"u}ning and Agnieszka Budzilowska and Bunker, {Clareann H} and Barbara Burwinkel and Ralf Butzow and Pedersen, {Inge Sokilde} and {Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2}",

note = "Copyright {\textcopyright} 2015. Published by Elsevier Inc.",

year = "2016",

doi = "10.1016/j.ygyno.2015.04.034",

language = "English",

volume = "141",

pages = "386--401",

journal = "Gynecologic Oncology",

issn = "0090-8258",

publisher = "Academic Press",

number = "2",

}

Hollestelle, A, van der Baan, FH, Berchuck, A, Johnatty, SE, Aben, KK, Agnarsson, BA, Aittomäki, K, Alducci, E, Andrulis, IL, Anton-Culver, H, Antonenkova, NN, Antoniou, AC, Apicella, C, Arndt, V, Arnold, N, Arun, BK, Arver, B, Ashworth, A, Baglietto, L, Balleine, R, Bandera, EV, Barrowdale, D, Bean, YT, Beckmann, L, Beckmann, MW, Benitez, J, Berger, A, Berger, R, Beuselinck, B, Bisogna, M, Bjorge, L, Blomqvist, C, Bogdanova, NV, Bojesen, A, Bojesen, SE, Bolla, MK, Bonanni, B, Brand, JS, Brauch, H, Brenner, H, Brinton, L, Brooks-Wilson, A, Bruinsma, F, Brunet, J, Brüning, T, Budzilowska, A, Bunker, CH, Burwinkel, B, Butzow, R, Pedersen, IS & Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2 2016, 'No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer', Gynecologic Oncology, vol. 141, no. 2, pp. 386-401. https://doi.org/10.1016/j.ygyno.2015.04.034

TY - JOUR

T1 - No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer

AU - Hollestelle, Antoinette

AU - van der Baan, Frederieke H

AU - Berchuck, Andrew

AU - Johnatty, Sharon E

AU - Aben, Katja K

AU - Agnarsson, Bjarni A

AU - Aittomäki, Kristiina

AU - Alducci, Elisa

AU - Andrulis, Irene L

AU - Anton-Culver, Hoda

AU - Antonenkova, Natalia N

AU - Antoniou, Antonis C

AU - Apicella, Carmel

AU - Arndt, Volker

AU - Arnold, Norbert

AU - Arun, Banu K

AU - Arver, Brita

AU - Ashworth, Alan

AU - Baglietto, Laura

AU - Balleine, Rosemary

AU - Bandera, Elisa V

AU - Barrowdale, Daniel

AU - Bean, Yukie T

AU - Beckmann, Lars

AU - Beckmann, Matthias W

AU - Benitez, Javier

AU - Berger, Andreas

AU - Berger, Raanan

AU - Beuselinck, Benoit

AU - Bisogna, Maria

AU - Bjorge, Line

AU - Blomqvist, Carl

AU - Bogdanova, Natalia V

AU - Bojesen, Anders

AU - Bojesen, Stig E

AU - Bolla, Manjeet K

AU - Bonanni, Bernardo

AU - Brand, Judith S

AU - Brauch, Hiltrud

AU - Brenner, Hermann

AU - Brinton, Louise

AU - Brooks-Wilson, Angela

AU - Bruinsma, Fiona

AU - Brunet, Joan

AU - Brüning, Thomas

AU - Budzilowska, Agnieszka

AU - Bunker, Clareann H

AU - Burwinkel, Barbara

AU - Butzow, Ralf

AU - Pedersen, Inge Sokilde

AU - Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2

PY - 2016

Y1 - 2016

N2 - OBJECTIVE: Clinical genetic testing is commercially available for rs61764370, an inherited variant residing in a KRAS 3' UTR microRNA binding site, based on suggested associations with increased ovarian and breast cancer risk as well as with survival time. However, prior studies, emphasizing particular subgroups, were relatively small. Therefore, we comprehensively evaluated ovarian and breast cancer risks as well as clinical outcome associated with rs61764370.METHODS: Centralized genotyping and analysis were performed for 140,012 women enrolled in the Ovarian Cancer Association Consortium (15,357 ovarian cancer patients; 30,816 controls), the Breast Cancer Association Consortium (33,530 breast cancer patients; 37,640 controls), and the Consortium of Modifiers of BRCA1 and BRCA2 (14,765 BRCA1 and 7904 BRCA2 mutation carriers).RESULTS: We found no association with risk of ovarian cancer (OR=0.99, 95% CI 0.94-1.04, p=0.74) or breast cancer (OR=0.98, 95% CI 0.94-1.01, p=0.19) and results were consistent among mutation carriers (BRCA1, ovarian cancer HR=1.09, 95% CI 0.97-1.23, p=0.14, breast cancer HR=1.04, 95% CI 0.97-1.12, p=0.27; BRCA2, ovarian cancer HR=0.89, 95% CI 0.71-1.13, p=0.34, breast cancer HR=1.06, 95% CI 0.94-1.19, p=0.35). Null results were also obtained for associations with overall survival following ovarian cancer (HR=0.94, 95% CI 0.83-1.07, p=0.38), breast cancer (HR=0.96, 95% CI 0.87-1.06, p=0.38), and all other previously-reported associations.CONCLUSIONS: rs61764370 is not associated with risk of ovarian or breast cancer nor with clinical outcome for patients with these cancers. Therefore, genotyping this variant has no clinical utility related to the prediction or management of these cancers.

AB - OBJECTIVE: Clinical genetic testing is commercially available for rs61764370, an inherited variant residing in a KRAS 3' UTR microRNA binding site, based on suggested associations with increased ovarian and breast cancer risk as well as with survival time. However, prior studies, emphasizing particular subgroups, were relatively small. Therefore, we comprehensively evaluated ovarian and breast cancer risks as well as clinical outcome associated with rs61764370.METHODS: Centralized genotyping and analysis were performed for 140,012 women enrolled in the Ovarian Cancer Association Consortium (15,357 ovarian cancer patients; 30,816 controls), the Breast Cancer Association Consortium (33,530 breast cancer patients; 37,640 controls), and the Consortium of Modifiers of BRCA1 and BRCA2 (14,765 BRCA1 and 7904 BRCA2 mutation carriers).RESULTS: We found no association with risk of ovarian cancer (OR=0.99, 95% CI 0.94-1.04, p=0.74) or breast cancer (OR=0.98, 95% CI 0.94-1.01, p=0.19) and results were consistent among mutation carriers (BRCA1, ovarian cancer HR=1.09, 95% CI 0.97-1.23, p=0.14, breast cancer HR=1.04, 95% CI 0.97-1.12, p=0.27; BRCA2, ovarian cancer HR=0.89, 95% CI 0.71-1.13, p=0.34, breast cancer HR=1.06, 95% CI 0.94-1.19, p=0.35). Null results were also obtained for associations with overall survival following ovarian cancer (HR=0.94, 95% CI 0.83-1.07, p=0.38), breast cancer (HR=0.96, 95% CI 0.87-1.06, p=0.38), and all other previously-reported associations.CONCLUSIONS: rs61764370 is not associated with risk of ovarian or breast cancer nor with clinical outcome for patients with these cancers. Therefore, genotyping this variant has no clinical utility related to the prediction or management of these cancers.

U2 - 10.1016/j.ygyno.2015.04.034

DO - 10.1016/j.ygyno.2015.04.034

M3 - Review article

C2 - 25940428

SN - 0090-8258

VL - 141

SP - 386

EP - 401

JO - Gynecologic Oncology

JF - Gynecologic Oncology

IS - 2

ER -

No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer

Abstract

Access to Document

AUB Link

Fingerprint

Cite this